Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | FDPS | P14324 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139602 | 1.00 | GPR84 (0.40) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL132225 | 1.00 | GPR84 (0.40) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL10776590 | 1.00 | GPR84 (0.40) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL27761435 | 0.98 | OPRM1 (0.39) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL11122020 | 0.90 | GPR84 (0.43) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL18636577 | 0.90 | GPR84 (0.43) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL11117118 | 0.90 | GPR84 (0.43) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL21199582 | 0.90 | GPR84 (0.43) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL21283607 | 0.90 | GPR84 (0.43) | GPR84FDPSFFAR1LMNAMAPT | |
| SCHEMBL6588124 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610248-B2 | Compositions and methods for treating influenza | VARIATION BIOTECHNOLOGIES, INC. (CA) | 2017-04-04 | — | — | US | claimed |
| EP-2590674-B1 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA | VARIATION BIOTECHNOLOGIES INC (CA) | 2017-02-22 | — | — | EP | claimed |
| EP-2451950-B9 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM | VARIATION BIOTECHNOLOGIES INC (CA) | 2016-11-23 | — | — | EP | claimed |
| EP-2451950-B1 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM | VARIATION BIOTECHNOLOGIES INC (CA) | 2016-03-02 | — | — | EP | claimed |
| US-20150290306-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT GLIOMAS | ANDERSON DAVID E (US) | 2015-10-15 | — | — | US | claimed |
| WO-2014070663-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT GLIOMAS | ANDERSON DAVID E (US) | 2014-05-08 | — | — | WO | claimed |
| US-20130108692-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA | VARIATION BIOTECHNOLOGIES, INC. (CA) | 2013-05-02 | — | — | US | claimed |
| JP-2011525190-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-20110097418-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA | VARIATION BIOTECHNOLOGIES, INC. (CA) | 2011-04-28 | — | — | US | claimed |
| WO-2009155489-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA | VARIATION BIOTECHNOLOGIES, INC. (CA) | 2009-12-23 | — | — | WO | claimed |
| US-12024552-B2 | Ha binding agents | Visterra, Inc. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240026407-A1 | MODIFICATION OF SAPONINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023242187-A1 | ENZYMATIC MODIFICATION OF SAPONINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259814-A2 | MODIFICATION OF SAPONINS | GlaxoSmithKline Biologicals SA (BE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023131885-A1 | SWALLOWABLE, SELF-EXPANDABLE DRUG DELIVERY DEVICE AND USES THEREOF | ETH ZURICH (CH) | 2023-07-13 | — | — | WO | disclosed |
| US-5721354-A | FOR TREATMENT OF INFECTIONS, MEDICAL DIAGNOSIS | AVIRON (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0821693-A1 | NOVEL HUMAN CYTOMEGALOVIRUS DNA SEQUENCES | AVIRON (US) | 1998-02-04 | — | — | EP | disclosed |
| EP-0769056-A1 | NON-SPLICING VARIANTS OF gp350/220 | AVIRON, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996030387-A1 | NOVEL HUMAN CYTOMEGALOVIRUS DNA SEQUENCES | AVIRON (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1995028488-A1 | NON-SPLICING VARIANTS OF gp350/220 | AVIRON (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026407-A1 | MODIFICATION OF SAPONINS | GBA3, SI, MANBA | GPR84 4614/4885FDPS 395/4885FFAR1 4437/4885 |
| US-12024552-B2 | Ha binding agents | HAVCR2, CD44, CD2BP2 | GPR84 2963/4885FDPS 4701/4885FFAR1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.